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Abstract In Alzheimer’s disease and related dementias, human
tau protein aggregates into paired helical filaments and
neurofibrillary tangles. However, such tau aggregates have not
yet been demonstrated in transgenic mouse models of the disease.
One of the possible explanations would be that mouse tau has
different properties which prevents it from aggregating. We have
cloned several murine tau isoforms, containing three or four
repeats and different combinations of inserts, expressed them in
Escherichia coli and show here that they can all be assembled
into paired helical filaments similar to those in Alzheimer’s
disease, using the same protocols as with human tau. Therefore,
the absence of pathologically aggregated tau in transgenic mice
cannot be explained by intrinsic differences in mouse tau protein
and instead must be explained by other as yet unknown factors.
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1. Introduction
The aggregation of the microtubule-associated protein
(MAP) tau into paired helical ¢laments (PHFs) and neuro-
¢brillary tangles (NFT) is one of the hallmarks of Alzheimer
disease (AD). Their density and spreading from the transen-
torhinal region to the neocortex can be used to subdivide the
progression of AD into six stages [10,3]. Besides AD, several
related dementias (e.g. corticobasal degeneration, Pick’s dis-
ease, prion diseases) show neuro¢brillary pathology and in
some cases, such as frontotemporal dementia with Parkinson-
ism, the disease correlates with mutations in the human tau
gene located on chromosome 17 [68,55,37,64,35,17,59,29].
Pathological tau aggregates have also been observed in aged
monkeys, dogs, bears, goats and sheep (e.g. [71,72,18,50,51]),
however, they have not been observed in rodents such as rats
or mice so far. Furthermore, transgenic animals carrying mu-
tations in genes involved in familial AD (e.g. the mutations in
amyloid precursor protein (APP) or presenilins, review [62])
have been shown to result in increased levels of the AL pep-
tide and deposition of amyloid plaques in a manner similar to
AD neuropathology, but no tau deposits have been seen
[24,46,36,65]. Similar amyloid changes occur in transgenic
mice bearing mutations in the presenilin gene with increases
in the AL40 and AL42 deposition [20,67,8], but so far, no
evidence of neuro¢brillary pathology has been reported.
Even the expression of human tau in transgenic mice did
not lead to tau aggregates [30,13].
One could hypothesize that the failure of tau to aggregate
in transgenic mouse models of AD may reside in the small but
signi¢cant di¡erences existing between the amino acid sequen-
ces of mouse and human. In the CNS, human tau can be
expressed in six isoforms arising from alternative splicing
[25,2] and a similar diversity exists in other animals. On the
protein level, four isoforms have been reported in adult bo-
vine tau [34] and three or four isoforms in adult rat or mouse
tau (rat: [41,40,49,21], mouse: [30,13]). The isoforms di¡er by
the presence or absence of one of the four pseudo-repeats in
the microtubule-binding domain and one or two near N-ter-
minal inserts (Fig. 1). In the case of humans, the smallest
isoform (3R-0N) has been shown to predominate in fetal
brain while adult brains contain a mixture of di¡erent iso-
forms with three or four repeats [25,27,12]. In rats, the small-
est isoform also dominates in fetal brain, whereas the adult
brain contains only the three isoforms with four repeats
[41,40,27,49]. Further ‘big tau’ isoforms exist in peripheral
nerves (mouse, human, rat [19,26,9] and non-neuronal cells
may contain tau as well [44,31]).
Tau was originally cloned from mouse in the 3-repeat ‘fetal’
form [43]. A comparison of human tau and mouse tau shows
some di¡erences in the N-terminal domain while the C-termi-
nal domain remains almost identical (Fig. 2). It is the C-ter-
minal region that is responsible for promoting microtubule
assembly as well as the aggregation of tau into PHFs, both
in vivo [70] and in vitro [69]. The N-terminal half of the
protein has been shown to inhibit PHF formation, but this
inhibition can be overcome in vitro by polyanionic cofactors
such as heparin, RNA or poly-Glu [54,28,39,33,22]. The sim-
ilarity of the microtubule-binding domain in human and
mouse tau suggests that both proteins should aggregate under
similar conditions. On the other hand, the occurrence of con-
servative missense mutations in the microtubule-binding re-
gion of human tau, which lead to the aggregation of tau in
tauopathies such as FTDP-17, indicates that even seemingly
subtle changes can have gross e¡ects on the tau function (see
references above and reviews by [63,45]).
In view of the importance of transgenic mouse models for
analyzing AD, these considerations make it necessary to test
the assembly behavior of mouse tau isoforms directly. Here,
we report that mouse brains show a transition from the small-
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est tau isoform (3R-0N) in fetal brain (appearing around E14)
to a mixture of three 4-repeat isoforms (4R-0N, -1N, -2N) in
the adult brain, reminiscent of rat brain. All isoforms are
capable of assembling into Alzheimer-like PHFs with a sim-
ilar e⁄ciency as human tau, using conditions similar to our
earlier studies with human tau [39,22,23]. This argues that
sequence di¡erences do not prevent the aggregation of mouse
tau and that other unknown mechanisms must inhibit assem-
bly of tau to AD-like PHFs in mice.
2. Materials and methods
2.1. Cloning of tau isoforms from mouse brain
Sequence data from mouse tau (accession number M18776) were
used to design primers to amplify the complete mTau encoding se-
quence by PCR. Primers used were mTauS1(EcoRI) 5P-GCGAA-
TTCCCTCTTCTGTCCTCGCCTTCTGTC-3P and mTauAS1(XhoI)
5P-GCCTCGAGGATTATTGACTGCCCTGGGAGCC-3P. PCR am-
pli¢cations were performed using a Marathon-Ready mouse brain
cDNA (Clontech) and the Expand High Fidelity PCR system (Boehr-
inger Mannheim) with 0.2 WM of each oligonucleotide. All PCR re-
actions were pre-heated to 95‡C for 5 min before the addition of
enzyme and included a ¢nal step of 7 min at 72‡C upon completion
of the ampli¢cation cycles. Cycling conditions were 45 s at 95‡C, 1 min
at 56‡C and 1 min and 30 s at 72‡C for 25 cycles. Three PCR products
corresponding in size to mTau 24, 34 and 40 (four repeats with 0, 1 or
2 inserts, terminology corresponding to human tau isoforms, [25])
were TA-cloned into pCR2.1 and screened by restriction digestion.
Several clones containing inserts of the appropriate size were fully
sequenced on both strands using ABI prism BigDye Terminator
Cycle sequencing kits and an Applied Biosystems 377XL sequencer
(Perkin Elmer, Foster City, USA). Sequencher software was used for
sequence assembly and manual editing (GeneCodes, Ann Arbor,
USA). Subcloning of the di¡erent mtau isoforms into the bacterial
expression vector pET21a (Novagen) was performed by PCR
ampli¢cation from mTau/pCR2.1 plasmid DNA using primers
mTauAS2(XhoI) 5P-GCCTCGAGCCTGATCACAAACCCTGCTT-
GGC-3P and mTauS3(NdeI) 5P-GCGAATTCCATATGGCTGACC-
CTCGGCAGG-3P. PCR fragments were gel-puri¢ed and sub-cloned
into dephosphorylated pET21a that was previously digested with the
appropriate restriction enzymes. The resulting expression constructs
were veri¢ed by complete sequence analysis as described earlier. The
shortest isoform mtau23 (3R-0N) was constructed as a chimaera from
a gene fragment encoding the N-terminal half of mouse tau (lacking
the N-terminal inserts) and the C-terminal half of human tau (con-
taining only three repeats). This construct contains one conservative
exchange (K257R) compared to the original mouse tau sequence ([43]
note that we use the numbering for human tau even for mouse tau
isoforms).
2.2. Preparation of mouse tau protein
Recombinant mouse Tau isoforms were expressed in Escherichia
coli and puri¢ed by FPLC MonoS (Pharmacia) chromatography as
described for the human Tau isoforms (e.g. [5]). For preparation of
tau from mouse brain (strain C57BlackJ6), total brain from adult or
embryonic mice (12^14 days) was homogenized in extraction bu¡er
(50 mM Na-PIPES pH 6.9, 500 mM NaCl, 5 mM EGTA, 50 mM
NaF, 0.5 mM PMSF, 1 mM Na3VO4, 5 mM DTT, 5 mM
Na2H2P2O7, 1 WM microcystin, 10 Wg/ml leupeptin, aprotinin and
pepstatin A) and centrifuged for 20 min at 14 000 rpm. The super-
natant was boiled for 10 min at 100‡C and recentrifuged. The super-
natant was acetone-precipitated, washed, dried and resuspended in 50
mM Tris, 5 mM MgCl2, pH 8.3. Samples for dephosphorylation were
dialyzed against 100 mM Tris-HCl pH 8.2. Dephosphorylation of tau
protein was done with alkaline phosphatase (Boehringer) at a concen-
tration of 400 U/ml for 20 h at 37‡C. The purity of the proteins was
analyzed by SDS-PAGE. Protein concentrations were determined by
the BCA method.
2.3. PHF assembly
Varying concentrations of mouse tau isoforms (typically in the
range of 50^200 WM) in volumes of 50 Wl were incubated at 37‡C in
100 mM Tris-HCl pH 6.8 up to 6 days. Protien solutions contained
various anionic cofactors: tRNA (from bovine liver), heparin (average
molecular weight (MW) of 3000), poly-L-glutamate (average MW of
1000) at approximately equimolar or indicated concentrations. All
chemicals were obtained from Sigma.
2.4. Electron microscopy
600-mesh-carbon-coated copper grids were glow-discharged twice
(CTA 010, Balzers Union). They were incubated on a drop of protein
solution for 1.5 min and negatively stained with 2% uranyl acetate for
0.5^1 min. The specimens were examined in a Philips CM12 electron
microscope at 100 kV.
2.5. Fluorescence spectroscopy
For the quanti¢cation of PHF assembly, £uorescence emission
spectra of thio£avine S (ThS, Sigma) bound to tau ¢laments were
measured with a Spex Fluoromax (Spex Instruments SA) with excita-
tion at 400 nm and emission at 500 nm (excitation and emission
bandwidths were set at 5 nm [22]). Filament formation was followed
by diluting the samples to 1 WM protein in 20 mM MOPS pH 7.0 in
the presence of 5 WM ThS.
2.6. Other methods
SDS gel electrophoresis was done on 8% polyacrylamide gels. Im-
munoblotting was done by transferring the proteins to an Immobilon
membrane (Millipore) and incubated with protein G a⁄nity-puri¢ed
polyclonal antibodies pAb-anti-insert1 (SA 4473), pAb-anti-insert2
(SA 4474) and pAb-anti-tau (K9JA). Non-speci¢c binding was
blocked by low-fat milk dissolved in TBS-Tween. The bound primary
antibody was detected by a peroxidase-conjugated secondary antibody
(anti-rabbit).
3. Results
The aim of this study was to determine whether mouse tau
isoforms were intrinsically able to form Alzheimer-like PHFs
in vitro, in a manner similar to human tau, or whether mouse
tau was su⁄ciently di¡erent such that PHF formation would
be prevented. We cloned the juvenile 3-repeat isoforms 3R-0N
([43] corresponding to the human fetal isoform htau23, [25]),
as well as the three 4-repeat isoforms containing 0, 1 or 2 near
N-terminal inserts (4R-0N, 4R-1N, 4R-2N, corresponding to
the human isoforms htau24, htau34, htau40; Fig. 1). In gen-
eral, the mouse isoforms are similar to their human counter-
parts. Changes occur almost exclusively in the N-terminal
projection domain, whereas the C-terminal assembly domains
are nearly identical (Fig. 2). In particular, mouse tau shows a
similar pattern of alternative splicing, having either three or
four pseudo-repeats (of 31 residues each) in the C-terminal
microtubule-binding domain and up to two inserts (of 29
residues each) in the N-terminal domain.
During embryonic development, no tau is present until day
Fig. 1. Diagrams of mouse tau isoforms used in this study. Due to
alternative splicing, there may be 0, 1 or 2 near N-terminal inserts
of 29 residues each (I1, I2), and three or four pseudo-repeats (31
residues) in the C-terminal half (R1^R4). The C-terminal half is re-
sponsible for microtubulus stabilisation and assembly of PHFs. Fe-
tal brain contains mainly the shortest isoform (3R-0N). Numbering
of residues is in analogy with human tau40.
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E13 (Fig. 3, lanes 1, 2). At E15, one observes two bands, a
major component (V70%) representing the smallest mouse
isoform containing three repeats and no inserts (mtau23,
3R-0N), followed by a minor component (V30%) containing
four repeats (mtau24, 4R-0N, Fig. 3, lanes 3, 4). This mixture
remains visible until at least E17. By contrast, adult mouse
brain contains only the three 4-repeat isoforms with 0, 1 or 2
inserts. This switch in the splicing pattern is analogous to that
in the rat or human brain [41,27,30,49], except that human
brain retains 3-repeat tau isoforms even in the adult stage.
For PHF assembly experiments, we expressed the fetal iso-
form 3R-0N and the three 4-repeat isoforms in E. coli and
prepared them as described previously [6]. The assembly con-
ditions were similar to those developed earlier for human tau.
In general, PHF formation is facilitated if one starts from a
solution of tau dimers which can be achieved by chemical
crosslinking at Cys-322 [69,61]. Secondly, the assembly pro-
ceeds most easily with tau constructs containing only the mi-
crotubule-binding domain, whereas the N-terminal domain
tends to prevent PHF assembly [69]. However, this inhibition
can be overcome by adding cellular polyanions, such as poly-
sulfates (heparin, [54,28]), polyphosphates [39] or polycarbox-
ylates (acidic peptides such as poly-Glu, [22]). Using these
principles, all mouse tau isoforms could be readily induced
Fig. 2. Amino acid sequence comparison of the longest tau isoforms
(4R-2N) in the CNS of humans and mice. Note that the assembly
domains of both proteins di¡er only in three amino acid residues
(human to mouse, S238A, A239S, K257R).
Fig. 3. Immunoblots of fetal and adult brain tau from mouse with
antibody (a) pAb-anti-Tau (K9JA), (b) pAb-anti-insert 1, (c) pAb-
anti-insert 2. Lanes 1 and 2: mouse tau from fetal brain day 13;
lanes 3 and 4: mouse tau from fetal brain day 15; lanes 5 and 6:
mouse tau from fetal brain day 17; lanes 7 and 8: mouse tau from
adult brain; lanes 9^12: recombinant mouse tau23 (3R-0N), mtau24
(4R-0N), mtau34 (4R-1N), mtau40 (4R-2N); lanes 13^15; recombi-
nant human tau, htau24, htau37, htau40. Lanes 1^8: protein tau
treated with (+) or without (3) alkaline phosphatase.
Fig. 4. Negative stain electron micrographs of PHFs assembled from mouse tau isoforms. (a) Fetal tau mtau23 (3R-0N), (b) mtau24 (4R-0N),
(c, d) mtau34 (4R-1N), (e) mtau40 (4R-2N). Assembly experiments were performed using 50^200 WM mouse tau in the presence of 150^200
WM heparin (a, b, d), 0.5 mg/ml RNA (c) or 200 WM poly-L-glutamate (e). Scale bar: 100 nm.
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to form PHF-like ¢laments. In the electron microscope, they
showed the typical two-stranded appearance, with crossover
repeats around 80 nm and widths varying between 10 and 20
nm (Fig. 4).
The assembly process could be monitored in real time using
an assay based on the £uorescence enhancement of ThS [22].
This shows that PHF assembly from mouse tau can be in-
duced by all three types of polyanions mentioned above, but
with di¡erent e⁄ciencies, in the order heparinsRNAs poly-
Glu (Fig. 5). This behavior is similar to that of human tau.
We therefore conclude that mouse tau is as able as human tau
to form PHFs in vitro.
4. Discussion
A pathological cascade has been proposed for AD begin-
ning with an altered metabolism of APP and leading to the
increased production of the L-amyloid peptide, subsequent
amyloid deposition, followed by the formation of NFTs and
¢nally leading to neuronal cell death [42,62]. In support of this
hypothesis, the link between APP, L-amyloid formation and
deposition has been demonstrated in transgenic mouse models
carrying the APP gene bearing di¡erent familial AD muta-
tions [16,36,46,20,24,58]. Thus far, these mouse models have
all failed to develop PHFs and NFTs, even though this neuro-
pathological hallmark is required to be present (as well as
amyloid plaques), by de¢nintion, in order for a positive diag-
nosis of AD to be given post-mortem [10,3]. To address this
problem directly, transgenic mice carrying the human tau gene
have been developed [30,13], but despite the elevated levels of
tau (human and total tau), these mouse models have also
failed to develop any neuro¢brillary pathology. The only
sign of tau alteration in APP or tau transgenic mice has
been a somewhat elevated level of tau phosphorylation at
the sites recognized by antibodies sensitive to phosphorylated
Ser-Pro or Thr-Pro motifs [30,13] or an altered conformation
recognized by the antibody Alz-50 [65,13]. However, altered
phosphorylation can be induced by several conditions such as
the fetal stage, hormone levels, phosphatase activity post-mor-
tem, AL toxicity [53,12,47,14,7]. Moreover, even when ‘aber-
rant’ levels of phosphorylation are detected, there is no indi-
cation of incipient PHF assembly. A similar lack of
correlation between tau phosphorylation and PHF assembly
is observed in cell models as well (e.g. [52,1,56]).
The most natural explanation for the absence of PHFs in
mice would be the inability of mouse tau to form PHFs. The
sequence alignment between human and mouse tau shows that
they are very similar, especially in the C-terminal half which is
important for PHF assembly (Fig. 1 and Fig. 2). Nevertheless,
even seemingly minor di¡erences could have large e¡ects on
self-assembly, as is impressively demonstrated by the point
mutations leading to the assembly of hemoglobin in sickle
cell anemia, transthyretin in systemic amyloidosis, prion pro-
tein in Creutzfeld-Jacob disease and others (reviews,
[66,15,32,57]). It was therefore necessary to test the in vitro
characteristics of mouse tau isoforms directly. The results
show that the di¡erences in the sequence between mouse
and human tau have no noticeable in£uence on the aggrega-
tion properties of the proteins. Thus, there must be di¡erent
explanations for the failure of mouse (or human) tau to ag-
gregate in transgenic mouse models. For example, it is possi-
ble that the factors that nucleate PHF formation in neurons
are di¡erent between mouse and human brains (in vitro they
are mimicked by polyanions such as heparin, RNA or poly-L-
glutamate). It is also conceivable that the isoform composition
matters for PHF aggregation in vivo. It has been shown that
rat and human brains have a transient stage where only the
smallest tau isoform with three repeats and no inserts occurs
[41,27] and the same is true for the mouse brain, as shown
here. By contrast, human brains di¡er from rodents in the
adult splicing pattern. Human tau is a mixture of six splicing
isoforms with three or four repeats, whereas only 4-repeat
forms occur in adult rodent tau. This di¡erence may be re-
lated to di¡erent stabilities of an mRNA stem loop at exon
10. However, this in itself cannot explain the failure of mouse
brains to develop PHFs since certain human Alzheimer-re-
lated tauopathies also show a preponderance of 4-repeat tau
isoforms [37,64].
Alzheimer tau di¡ers from normal tau not only in terms of
aggregation, but also in terms of post-translational modi¢ca-
tions, notably phosphorylation. It is possible that the modi¢-
cations of mouse tau are di¡erent from those of human tau
which could subsequently a¡ect aggregation. On the basis of
current knowledge however, this is not likely, since the assem-
bly of PHFs in vitro can be achieved independently of phos-
phorylation [69]. A debate on whether abnormal phosphoryl-
ation promotes PHF aggregation has continued for some
time and changes in the phosphorylation are often regarded
as hallmarks of incipient aggregation. Indeed, phosphoryla-
tion appears to precede tangle formation in degenerating neu-
rons [4,11]. In several mouse lines, increased levels of phos-
phorylation have been observed, e.g. cells from mice carrying
human APP mutations [24,65], cells overexpressing the kinase
mos [38] or overexpressing human tau [30,13]. However, the
fact that none of these models have developed tangles would
argue that phosphorylation does not necessarily predispose
tau for aggregation. This is consistent with our recent ¢ndings
that phosphorylation protects tau against aggregation, rather
than promoting it [60]. Nevertheless, it is still possible that
other modi¢cations such as glycation or transglutamination
may cause PHF aggregation in humans but not in mice
[73,74,48]. These modi¢cations have yet to be characterized
for mouse brain tau.
Fig. 5. Assembly kinetics of mtau24 (4R-0N) (50 WM) using the
ThS £uoresence assay [22]. (a) In the presence of poly-L-glutamate
(200 WM) or (b) in the presence of heparin (50 WM).
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